Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04181736 · ClinicalTrials.gov registry record · Phase 4
The BIomarker Guided (BIG) Study for Depression
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT04181736: Completed Phase 4 study, sponsored by Stanford University.
NCT04181736 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04181736, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
Cognitive impairments contribute significantly to psychosocial dysfunction in major depressive disorder (MDD) and respond poorly to conventional antidepressants, yet selective treatments targeted to these impairments are lacking. Our previous research identified a distinct subgroup of depression called "cognitive biotype+" that comprises 27% of depressed patients and is characterized by pre-treatment global cognitive impairments and dysfunction in the cognitive control neural circuit. In this study, we evaluated the medication guanfacine immediate release (GIR), an alpha 2A receptor agonist, as a novel treatment for selectively improving cognitive control circuit function, performance on cognitive testing, and clinical measures the cognitive biotype+ subgroup.
Interventions
- DRUG Guanfacine Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-09-14 |
| Est. Completion | 2024-02-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04181736
The ClinicalTrials.gov registry entry for NCT04181736 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guanfacine Tablets is the first listed.
NCT04181736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04181736 about?
NCT04181736 is a clinical study titled "The BIomarker Guided (BIG) Study for Depression". Cognitive impairments contribute significantly to psychosocial dysfunction in major depressive disorder (MDD) and respond poorly to conventional antidepressants, yet selective treatments targeted to these impairments are lacking. Our previous research identified a distinct subgroup of depression cal...
What is the current status of trial NCT04181736?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2022-09-14. Estimated completion is 2024-02-12.
What interventions are being tested in trial NCT04181736?
The interventions under investigation include: Guanfacine Tablets (DRUG).
Who is sponsoring clinical trial NCT04181736?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.